Literature DB >> 21185158

Actin dynamics regulate immediate PAR-2-dependent responses to acute epidermal permeability barrier abrogation.

Truus Roelandt1, Carol Heughebaert, Gunther Verween, Christina Giddelo, Gilbert Verbeken, Jean-Paul Pirnay, Daniel Devos, Debra Crumrine, Diane Roseeuw, Peter M Elias, Jean-Pierre Hachem.   

Abstract

BACKGROUND: Lamellar body (LB) secretion and terminal differentiation of stratum granulosum (SG) cells are signaled by both protease activated receptor-2 (PAR-2) and caveolin-1 (cav-1).
OBJECTIVE: To address the early dynamics of LB secretion, we examined cytoskeletal remodeling of keratinocytes in 3 mouse models following acute barrier abrogation: hairless mice, PAR-2 knockout (-/-) and cav-1 -/-. METHODS AND
RESULTS: Under basal conditions, globular (G)-actin accumulates in SG cells cytosol, while filamentous (F)-actin is restricted to peri-membrane domains. Barrier abrogation induces the apical movement of F-actin and the retreat of the SG-G-actin front, paralleled by upstream cytoskeletal kinases activation. This phenomenon was both enhanced by PAR-2 agonist, and inhibited by cytochalasin-D and in PAR-2 knockout mice. We found that plasma membrane conformational changes causing LB secretion are controlled by PAR-2-dependent cytoskeletal rearrangements. We next addressed the interaction dynamics between cytoskeleton and plasma membrane following PAR-2-induced actin stress fiber formation in both cav-1 -/- and wildtype cells. Actin stress fiber formation is increased in cav-1 -/- cells prior to and following PAR-2 agonist peptide-treatment, while absence of cav-1 inhibits E-cadherin-mediated cell-to-cell adhesion.
CONCLUSION: PAR-2 drives cytoskeletal/plasma membrane dynamics that regulate early LB secretion following barrier abrogation, stress fiber formation and keratinocyte adhesion.
Copyright © 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185158     DOI: 10.1016/j.jdermsci.2010.11.016

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  Hepatocyte growth factor activator inhibitor type 1 maintains the assembly of keratin into desmosomes in keratinocytes by regulating protease-activated receptor 2-dependent p38 signaling.

Authors:  Makiko Kawaguchi; Ai Kanemaru; Akira Sawaguchi; Koji Yamamoto; Takashi Baba; Chen-Yong Lin; Michael D Johnson; Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Am J Pathol       Date:  2015-04-01       Impact factor: 4.307

2.  Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist.

Authors:  Hyo Young Kim; Jung Hyun Goo; Yeon Ah Joo; Ha Yoen Lee; Se Mi Lee; Chang Taek Oh; Soo Mi Ahn; Nam-Hoon Kim; Jae Sung Hwang
Journal:  Biomol Ther (Seoul)       Date:  2012-09       Impact factor: 4.634

3.  Caspase-14 expression impairs retinal pigment epithelium barrier function: potential role in diabetic macular edema.

Authors:  Selina Beasley; Mohamed El-Sherbiny; Sylvia Megyerdi; Sally El-Shafey; Karishma Choksi; Ismail Kaddour-Djebbar; Nader Sheibani; Stephen Hsu; Mohamed Al-Shabrawey
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

4.  Electrospun tube reduces adhesion in rabbit Achilles tendon 12 weeks post-surgery without PAR-2 overexpression.

Authors:  Gabriella Meier Bürgisser; Olivera Evrova; Dorothea M Heuberger; Petra Wolint; Julia Rieber; Iris Miescher; Reto A Schüpbach; Pietro Giovanoli; Maurizio Calcagni; Johanna Buschmann
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

5.  Orchestrated control of filaggrin-actin scaffolds underpins cornification.

Authors:  Danuta Gutowska-Owsiak; Jorge Bernardino de La Serna; Marco Fritzsche; Aishath Naeem; Ewa I Podobas; Michael Leeming; Huw Colin-York; Ryan O'Shaughnessy; Christian Eggeling; Graham S Ogg
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.